Drug Patent List
Expedited Drug ApprovalsNew
Newsletter
Weekly Digest

Pharsight

Eli Lilly And Co Drug Patent Portfolio

Eli Lilly And Co's Family Patents


Family Patents





Clinical Trials

Recent Clinical Trials by Eli Lilly And Co:

Title Lead Sponsor Collaborators Status Phases
Clinical Trials
A Study of Tirzepatide (LY3298176) in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes Eli Lilly and Company NA RECRUITING
(Sep, 2024)
PHASE2
A Study of LY3841136 in Overweight and Obese Participants Eli Lilly and Company NA ACTIVE NOT RECRUITING
(Sep, 2024)
PHASE1
A Study of Tirzepatide (LY3298176) in Adult Participants With Type 2 Diabetes Switching From Dulaglutide (SURPASS-SWITCH) Eli Lilly and Company NA COMPLETED
(Aug, 2024)
PHASE4
A Study of Tirzepatide (LY3298176) Plus Mibavademab Compared With Tirzepatide Alone in Adult Participants With Obesity Eli Lilly and Company Regeneron Pharmaceuticals RECRUITING
(Aug, 2024)
PHASE2
A Study of Tirzepatide (LY3298176) in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF) and Obesity: The SUMMIT Trial Eli Lilly and Company NA COMPLETED
(Jul, 2024)
PHASE3
A Study of LY3298176 (Tirzepatide) For the Maintenance of Body Weight Reduction in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities Eli Lilly and Company NA ACTIVE NOT RECRUITING
(Jul, 2024)
PHASE3
A Study of Tirzepatide (LY3298176) in Participants With Nonalcoholic Steatohepatitis (NASH) Eli Lilly and Company NA COMPLETED
(Apr, 2024)
PHASE2
A Study of Tirzepatide (LY3298176) in Japanese Participants With Type 2 Diabetes Eli Lilly and Company NA COMPLETED
(Jun, 2022)
PHASE1
A Study of Tirzepatide (LY3298176) Once a Week Versus Insulin Glargine Once a Day in Participants With Type 2 Diabetes and Increased Cardiovascular Risk Eli Lilly and Company NA COMPLETED
(Jan, 2022)
PHASE3


Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List

Eli Lilly And Co News

Novo Nordisk A/S shares (DK0062498333): Can its leading position in obesity medications sustain...

19 Apr, 2026

Amgen Inc. shares (US0311621009): Can the momentum of its obesity medication maintain long-term growth?

14 Apr, 2026

Rothschild & Co Redburn Increases Eli Lilly's Price Target to $880 - Indianapolis Today

11 Apr, 2026

Exploring Eli Lilly's $7.8 Billion Purchase of Centessa Pharmaceuticals: The Orexin Boom

01 Apr, 2026

See More